C4X Discovery Holdings plc (C4XD) Ordinary Shares 1p
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
C4X Discovery shares soar on $11m COPD payment from AstraZeneca
3 January 2024 07:12
(Sharecast News) - C4X Discovery, the AIM-listed drug discovery company, has received a "milestone payment" of $11m from biopharma giant AstraZeneca as part of the progress of its NRF2 Activator...
-
C4X Discovery launches new precision medicine platform
22 February 2023 12:43
(Sharecast News) - C4X Discovery launched a new precision medicine platform called 'PatientSeek' on Wednesday, after a successful research collaboration with the Garvan Institute of Medical Research.
-
C4X makes positive progress with potential cancer programme
19 January 2023 16:14
(Sharecast News) - C4X Discovery updated on its 'MALT-1' inhibitor programme on Thursday, explaining that the overexpression or over-activation of MALT-1 has been observed in a range of lymphomas...
-
C4X promotes Nick Ray to chief scientific officer
10 January 2023 15:38
(Sharecast News) - Drug discovery company C4X announced the appointment of Nick Ray as its chief scientific officer on Tuesday, with immediate effect.
-
C4X Discovery signs up-to-$402m deal with AstraZeneca
28 November 2022 14:02
(Sharecast News) - Drug discovery specialist C4X has signed an exclusive worldwide licensing agreement with AstraZeneca worth up to $402m, it announced on Monday, for its 'NRF2 Activator' programme.
-
C4X raises £5.7m to support development activities
11 August 2022 15:39
(Sharecast News) - Drug discovery company C4X announced a proposed placing to raise up to £5.7m on Thursday, to support its corporate development and ongoing commercial activities.
-
C4X Discovery appoints Cathy Tralau-Stewart as new science chief
21 December 2021 12:57
(Sharecast News) - Drug discovery company C4X announced the appointment of Catherine Tralau-Stewart as its new chief scientific officer on Tuesday, effective from 4 January.
-
C4X Discovery signs exclusive licensing deal with Sanofi
12 April 2021 08:41
(Sharecast News) - C4X Discovery has signed an exclusive worldwide licensing agreement with Sanofi worth up to €414m (£357.84m), it announced on Monday, for its oral preclinical IL-17A inhibitor programme.
Company announcements Announcements
-
Proposed Voluntary Delisting
27 March 2024 07:00
C4X Discovery Holdings
-
Interim results
27 March 2024 07:00
C4X Discovery Holdings
-
Result of AGM
23 January 2024 13:57
C4X Discovery Holdings
-
Board Update
18 January 2024 07:00
C4X Discovery Holdings
-
Holding(s) in Company
4 January 2024 14:45
C4X Discovery Holdings
-
AstraZeneca $11m milestone payment to C4XD
3 January 2024 07:00
C4X Discovery Holdings
-
Posting of 2023 Annual Report and Notice of AGM
18 December 2023 15:31
C4X Discovery Holdings
-
Full Year Results
14 December 2023 07:00
C4X Discovery Holdings
-
Notice of Results
7 December 2023 07:00
C4X Discovery Holdings
-
Holding(s) in Company
5 October 2023 14:35
C4X Discovery Holdings
-
Block listing Interim Review
2 October 2023 12:36
C4X Discovery Holdings
-
Grant of Options and Directors Dealing
29 September 2023 11:14
C4X Discovery Holdings
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.